Alice Chen-Plotkin, MD, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, provides an insight into precision medicine approaches under investigation in Parkinson’s disease (PD). One interesting line of investigation aims to establish a tool to predict the development of impulse control disorders (ICDs) in patients treated with dopamine agonists. Triggering an ICD in a patient subjects them to a complicated and time-consuming process of withdrawing treatment and starting a new treatment regimen with levodopa. Thus, predicting the likelihood of developing an ICD in a patient with PD could bypass this process. Dr Chen-Plotkin details the development of a genetic and clinical predictor that uses single nucleotide polymorphisms (SNPs) and clinical variables to risk stratify patients. There is also a gap in our understanding of delaying or preventing cognitive decline and dementia in patients with PD. Post-mortem examination of brain tissue from patients with a primary diagnosis of PD indicates that a large proportion of patients also develop Alzheimer’s disease (AD) pathology. Dr Chen-Plotkin outlines work aiming to stratify patients according to their chance of developing AD pathology. This interview took place during the 2021 International Congress of Parkinson's Disease and Movement Disorders.

свернуть